

PureGG 25B

SUPPORTS IMMUNE, GI, AND OVERALL HEALTH[‡]



PureGG 25B provides 25 billion CFU of *Lactobacillus rhamnosus* GG (LGG), one of the most extensively studied, clinically documented and widely utilized probiotic strains. The efficacy and uses of LGG have been recognized in hundreds of clinical trials across all age groups, including children and pregnant women. It is well known for its favorable effects on bowel function particularly abdominal comfort, bowel motility and occasional diarrhea.[‡]



Supports healthy gut microflora[‡]



Promotes bowel function[‡]



Supports healthy immune balance[‡]

LGG was first isolated in 1983 from a human donor by Dr. Sherwood Gorbach and Dr. Barry Goldin (the "GG" namesake) and patented in 1985. It has been in clinical use since 1990. Originally selected for its resilience and colonization properties in the GI tract, LGG exhibits well-characterized resilience in the GI tract, with robust acid and bile tolerance. Pili on the cell surface of LGG express unique proteins enable adhesion and adequate contact with intestinal epithelial cells. These interactions facilitate beneficial effects on mucosal integrity, immunity and motility.^{1-10[‡]}

WHO IS THIS SUPPLEMENT FOR?

- Patients with occasional abdominal discomfort and/or diarrhea
- Patients seeking immune support

MECHANISMS OF ACTION[‡]

LGG promotes cytokine balance in the GI tract at the level of gene expression, and provides general immunomodulatory support.^{1,7-9} In preclinical models, LGG also supports the intestinal barrier integrity and mucin production.¹



Proposed mechanisms of action of *Lactobacillus rhamnosus* GG (LGG) in the gastrointestinal tract.




Figure 1. LGG supports gastrointestinal and immune health through multiple complementary mechanisms. These include (1) promotion of a balanced gut microbiota, (2) modulation of cytokine signaling to help maintain immune homeostasis, (3) immune cell activity within the intestinal mucosa, and (4) production of beneficial microbial metabolites that contribute to gut ecosystem stability and host physiology.

[‡]This statement has not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

CLINICAL RESEARCH HIGHLIGHTS†

Occasional diarrhea and abdominal comfort

- In a study involving 820 people traveling on holiday to southern Turkey, LGG supplementation resulted in significant support for occasional diarrhea, particularly for older individuals, compared to placebo.³
- In a study involving 141 children with abdominal discomfort, supplementation for 12 weeks offered significant support for abdominal comfort and intestinal integrity.⁴

Immunomodulation in the GI tract

- In a clinical trial, LGG supplementation promoted healthy gene expression to support white blood cell (WBC) function. Elderly subjects who received LGG for 28 days showed 95 differentially expressed genes related to cellular movement, cell-to-cell signaling, and cytokine response.⁹
- In a double-blind, crossover study, supplementation moderated the neutrophil and monocyte immune response in dairy-challenged milk-sensitive subjects, while promoting immune function in non-sensitive subjects.¹⁰

Gut microbiota

- In a clinical study, infants whose mothers had received LGG during the last weeks of pregnancy showed increased bifidobacterial diversity at 5 days of age.⁶

Respiratory and immune health

- In a study involving children ages 1-7 attending day care, supplementation showed statistically significant support for upper respiratory tract health and immune function.⁸

REFERENCES

1. Leser T et al. *Microorganisms*. 2024 Apr 14;12(4):794.
2. Pace F et al. *Minerva Gastroenterol Dietol*. 2015;61(4):273-292.
3. Oksanen PJ et al. *Ann Med*. 1990;22(1):53-56.
4. Francavilla R et al. *Pediatrics*. 2010;126(6):e1445-1452.
5. Vendt N et al. *J Hum Nutr Diet*. 2006;19(1):51-58.
6. Gueimonde M et al. *J Pediatr Gastroenterol Nutr*. 2006;42(2):166-170.
7. Kalliomaki M et al. *Lancet*. 2001;357(9262):1076-1079.
8. Hojsak I et al. *Clin Nutr*. 2010;29(3):312-316.
9. Salano-Aguilar G et al. *PLoS One*. 2016;11(2):e0147426.
10. Pelto L et al. *Clin Exp Allergy*. 1998;28(12):1474-1479.

Visit PureEncapsulationsPro.com/quality for more information on our GMO policy.

0.905 in



1 capsule daily, with or between meals.

Each vegetarian capsule contains:

Lactobacillus rhamnosus GG 25 billion CFU

Other ingredients: vegetarian capsule (cellulose, water)

Gastrointestinal Health



PureGG 25B

Quantity Order Code

60 PGG6

†This statement has not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.



800.753.2277 | PureEncapsulationsPro.com

Pure Encapsulations is a registered trademark.

pure
encapsulations®